Trade IQVIA Holdings Inc. - IQV CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1.99
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 271.46
• Open: 271.57
• 1-Year Change: 33.77%
• Day's Range: 263.28 - 271.57

Trade IQVIA Holdings Inc. - IQV

About Iqvia Holdings Inc

IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company’s segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions, which primarily serves biopharmaceutical clients, is engaged in research and development and provides clinical research and clinical trial services. Contract Sales & Medical Solutions provides contract sales to both biopharmaceutical clients and the broader healthcare market.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Iqvia Holdings Inc revenues increased 22% to $13.87B. Net income increased from $279M to $966M. Revenues reflect Research & Development Solutions segment increase of 31% to $7.56B, Technology & Analytics Solutions segment increase of 14% to $5.53B, Contract Sales & Medical Solutions segment increase of 6% to $784M.

Equity composition

Common Stock $0.01 Par, 05/13/, Shares auth. 150M., 129,606,179 issd. Insiders owns approx. 84.77%